Advanced Centre for Treatment, Research and Education in Cancer, Navi Mumbai, India.
Homi Bhabha National Institute, Mumbai, India.
FEBS J. 2024 Apr;291(7):1422-1438. doi: 10.1111/febs.17041. Epub 2023 Dec 28.
Acute promyelocytic leukemia (APL) is characterized by the fusion gene promyelocytic leukemia-retinoic acid receptor-alpha (PML-RARA) and is conventionally treated with arsenic trioxide (ATO). ATO binds directly to the RING finger, B-box, coiled-coil (RBCC) domain of PML and initiates degradation of the fusion oncoprotein PML-RARA. However, the mutational hotspot at C212-S220 disrupts ATO binding, leading to drug resistance in APL. Therefore, structural consequences of these point mutations in PML that remain uncertain require comprehensive analysis. In this study, we investigated the structure-based ensemble properties of the promyelocytic leukemia-RING-B-box-coiled-coil (PML-RBCC) domains and ATO-resistant mutations. Oligomeric studies reveal that PML-RBCC wild-type and mutants C212R, S214L, A216T, L217F, and S220G predominantly form tetramers, whereas mutants C213R, A216V, L218P, and D219H tend to form dimers. The stability of the dimeric mutants was lower, exhibiting a melting temperature (T) reduction of 30 °C compared with the tetrameric mutants and wild-type PML protein. Furthermore, the exposed surface of the C213R mutation rendered it more prone to protease digestion than that of the C212R mutation. The spectroscopic analysis highlighted ATO-induced structural alterations in S214L, A216V, and D219H mutants, in contrast to C213R, L217F, and L218P mutations. Moreover, the computational analysis revealed that the ATO-resistant mutations C213R, A216V, L217F, and L218P caused changes in the size, shape, and flexibility of the PML-RBCC wild-type protein. The mutations C213R, A216V, L217F, and L218P destabilize the wild-type protein structure due to the adaptation of distinct conformational changes. In addition, these mutations disrupt several hydrogen bonds, including interactions involving C212, C213, and C215, which are essential for ATO binding. The local and global structural features induced by these mutations provide mechanistic insight into ATO resistance and APL pathogenesis.
急性早幼粒细胞白血病（APL）的特征是存在早幼粒细胞白血病-维甲酸受体-α（PML-RARA）融合基因，通常采用三氧化二砷（ATO）进行治疗。ATO 直接与 PML 的 RING 指、B 盒、卷曲螺旋（RBCC）结构域结合，引发融合癌蛋白 PML-RARA 的降解。然而，C212-S220 热点突变会破坏 ATO 的结合，导致 APL 耐药。因此，需要对 PML 中这些点突变的结构后果进行全面分析。在这项研究中，我们研究了早幼粒细胞白血病-RING-B 盒-卷曲螺旋（PML-RBCC）结构域和 ATO 耐药突变的基于结构的整体特性。寡聚研究表明，PML-RBCC 野生型和突变型 C212R、S214L、A216T、L217F 和 S220G 主要形成四聚体，而突变型 C213R、A216V、L218P 和 D219H 则倾向于形成二聚体。二聚体突变体的稳定性较低，与四聚体突变体和野生型 PML 蛋白相比，其熔点（T）降低了 30°C。此外，C213R 突变的暴露表面使其比 C212R 突变更容易被蛋白酶消化。光谱分析突出了 S214L、A216V 和 D219H 突变体中 ATO 诱导的结构改变，而 C213R、L217F 和 L218P 突变则没有。此外，计算分析表明，ATO 耐药突变 C213R、A216V、L217F 和 L218P 导致 PML-RBCC 野生型蛋白的大小、形状和柔韧性发生变化。突变 C213R、A216V、L217F 和 L218P 由于适应不同的构象变化，导致野生型蛋白结构不稳定。此外，这些突变破坏了几个氢键，包括涉及 C212、C213 和 C215 的相互作用，这些相互作用对于 ATO 结合是必不可少的。这些突变引起的局部和整体结构特征为 ATO 耐药和 APL 发病机制提供了机制见解。
